drugset / Trial / NCT05333302

Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

NCT05333302

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children/young adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.

Timeline

Start
2020-10-26
Primary completion
2024-12
Completion
2025-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19 CAR-T cells Cell therapy 1e+06 cells/kg Intravenous
Background Tocilizumab Monoclonal antibody 8 mg/kg